Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors.
نویسندگان
چکیده
PURPOSE To determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic characteristics of doxorubicin encapsulated in a low temperature sensitive liposome (LTSL) when given concurrently with local hyperthermia to canine solid tumors. EXPERIMENTAL DESIGN Privately owned dogs with solid tumors (carcinomas or sarcomas) were treated. The tumors did not involve bone and were located at sites amenable to local hyperthermia. LTSL-doxorubicin was given (0.7-1.0 mg/kg i.v.) over 30 minutes during local tumor hyperthermia in a standard phase I dose escalation study. Three treatments, given 3 weeks apart, were scheduled. Toxicity was monitored for an additional month. Pharmacokinetics were evaluated during the first treatment cycle. RESULTS Twenty-one patients were enrolled: 18 with sarcomas and 3 with carcinomas. Grade 4 neutropenia and acute death secondary to liver failure, possibly drug related, were the dose-limiting toxicities. The maximum tolerated dose was 0.93 mg/kg. Other toxicities, with the possible exception of renal damage, were consistent with those observed following free doxorubicin administration. Of the 20 dogs that received > or = 2 doses of LTSL-doxorubicin, 12 had stable disease, and 6 had a partial response to treatment. Pharmacokinetic variables were more similar to those of free doxorubicin than the marketed liposomal product. Tumor drug concentrations at a dose of 1.0 mg/kg averaged 9.12 +/- 6.17 ng/mg tissue. CONCLUSION LTSL-doxorubicin offers a novel approach to improving drug delivery to solid tumors. It was well tolerated and resulted in favorable response profiles in these patients. Additional evaluation in human patients is warranted.
منابع مشابه
Doxorubicin Loaded Liposomal Nanoparticles Containing Quantum Dot for Treatment of Breast Cancer
In addition to increasing the efficacy of various drugs, Nanoparticles reduce their side effects. In this study, different nanoparticle formulations of Doxorubicin anticancer drugs were prepared. The efficacy of the formulations produced in the cell culture medium was studied compared with the free drug. Reverse phase evaporation was used to form the liposome containing do...
متن کاملPulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect.
PURPOSE To determine if pulsed-high intensity focused ultrasound (HIFU) could effectively serve as a source of hyperthermia with thermosensitive liposomes to enhance delivery and efficacy of doxorubicin in tumors. EXPERIMENTAL DESIGN Comparisons in vitro and in vivo were carried out between non-thermosensitive liposomes (NTSL) and low temperature-sensitive liposomes (LTSL). Liposomes were inc...
متن کاملTemperature-sensitive liposomes containing doxorubicin and manganese for MR Imaging-guided drug delivery
متن کامل
Chemotherapeutic activity of Silymarin combined with doxorubicin liposomes in 4T1 breast cancer cells
Cancer is the second leading cause of death worldwide. Despite great efforts over many years, today cancer treatment is not very effective. The main reasons for cancer chemotherapy failure are high cytotoxicity, low response rates in solid tumors, and development of resistance. Different experimental studies have shown that drug combination using low toxicity natural compounds such as polypheno...
متن کاملThermosensitive liposomal drug delivery systems: state of the art review
Thermosensitive liposomes are a promising tool for external targeting of drugs to solid tumors when used in combination with local hyperthermia or high intensity focused ultrasound. In vivo results have demonstrated strong evidence that external targeting is superior over passive targeting achieved by highly stable long-circulating drug formulations like PEGylated liposomal doxorubicin. Up to M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical cancer research : an official journal of the American Association for Cancer Research
دوره 12 13 شماره
صفحات -
تاریخ انتشار 2006